Infectologia

Análise secundária de estudo randomizado aponta que tocilizumabe é benéfico para pacientes hospitalizados com Covid-19 se os níveis de PCR forem maiores que 15 mg/dL, mas não se tais níveis forem de 15 mg/dL ou menos.

25 Mai, 2021 | 15:51h

Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial – JAMA Internal Medicine

Estudo mostra que COVID-19 leve induz proteção duradoura por anticorpos.

25 Mai, 2021 | 15:50h

Mild COVID-19 induces lasting antibody protection, study finds – Washington University School of Medicine

Estudo original: SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans – Nature

Comentário no Twitter (fio – clique para saber mais)

Just published @nature
After even mild covid infections there are, in addition to memory B cells, bone marrow plasma cells are induced to provide long-term protection > 1 yrhttps://t.co/zVfUFvciVk @TheBcellArtist @WUSTLmed
(NB vaccination still provides further protection) pic.twitter.com/rUd8pMAP1T

— Eric Topol (@EricTopol) May 24, 2021

OMS: Pelo menos 115.000 profissionais da saúde morreram de COVID.

25 Mai, 2021 | 15:49h

At least 115,000 health workers have died from COVID: WHO – MedicalXpress

Perspectiva | Coronavírus: muitas variantes, mas as vacinas continuam eficazes.

25 Mai, 2021 | 15:48h

C oronavirus: so many variants, but vaccines are still effective – The Conversation

OMS: O impacto da COVID-19 nas metas globais de saúde – A doença foi responsável por, pelo menos, 3 milhões de mortes a mais em 2020.

24 Mai, 2021 | 11:09h

The impact of COVID-19 on global health goals – World Health Organization

Relacionado: Covid-19 pandemic: approximately one million excess deaths occurred in 2020 in 29 high income countries. E Perspective | Tracking lives we’ve lost to COVID-19. E COVID-19 has caused 6.9 million deaths globally, more than double what official reports show

Comentário no Twitter (fio – clique para saber mais)

🆕 The latest World Health Statistics report finds that #COVID19 is responsible for at least 3 million excess deaths in 2020 👉 https://t.co/yAXB5bzx1g #HealthData pic.twitter.com/DMd9fg69I2

— World Health Organization (WHO) (@WHO) May 21, 2021

[Preprint] Estudo randomizado: Coquetéis de anticorpos REGEN-COV, tanto de 2.400 mg quanto de 1.200 mg, reduziram significativamente as hospitalizações relacionadas a Covid-19 ou mortes por todas as causas em comparação ao placebo (redução de 71,3% e 70,4%, respectivamente).

24 Mai, 2021 | 11:07h

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients – medRxiv

Comentário no Twitter

REGEN-COV Antibody Cocktail(casirivimab with imdevimab) Clinical Outcomes Study in Covid-19 Outpatients: N:>4000 pts
Both 1200mg IV&2400mg REGEN-COV led to a ≥70% ⬇️ (vs placebo) in Covid-19 hospitalization or all-cause death over 28 days after treatmenthttps://t.co/NJxF4BjZRs pic.twitter.com/CFdvEEIWEL

— Antibiotic Steward 🇵🇸💔Bassam Ghanem (@ABsteward) May 21, 2021

[Preprint] Efetividade da vacina CoronaVac na população idosa durante a epidemia de COVID-19 associada à variante P.1 no Brasil – “CoronaVac foi 42% efetiva no cenário de mundo real de extensa transmissão de P1, mas não se observou uma proteção significativa até a conclusão do regime de duas doses.”

24 Mai, 2021 | 11:06h

Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study – medRxiv

[Preprint] Vacinas da Pfizer e da AstraZeneca são eficazes contra a variante B.1.617.2 depois de 2 doses.

24 Mai, 2021 | 11:03h

Comunicado de imprensa: Vaccines highly effective against B.1.617.2 variant after 2 doses – Public Health England

Estudo original: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – Public Health England

Comentário: Covid: Pfizer and AstraZeneca jabs effective against Indian variant – study – BBC

CDC investiga diversos relatos de adolescentes e adultos jovens que podem ter desenvolvido miocardite após receber vacinas de mRNA. A maioria dos casos é leve, mais frequente no sexo masculino, mais comum após a 2ª dose e ocorre tipicamente dentro de 4 dias após a vacinação.

24 Mai, 2021 | 11:02h

COVID-19 VaST Work Group Technical Report – May 17, 2021 – Centers for Disease Control and Prevention

Comentários: C.D.C. Is Investigating a Heart Problem in a Few Young Vaccine Recipients – The New York Times E U.S. CDC looking into heart inflammation in some young vaccine recipients – Reuters

Relacionado: Israel said probing link between Pfizer shot and heart problem in men under 30 – The Times of Israel

M-A: Tocilizumabe na COVID-19 – “Há algumas evidências de que, em pacientes hospitalizados com COVID-19, o uso de tocilizumabe possa estar associado com o benefício de mortalidade de curto prazo, mas são necessários mais dados de alta qualidade.”

24 Mai, 2021 | 11:01h

Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials – Intensive Care Medicine